Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Mikkelsen, Tom  [Clear All Filters]
2014
Assi HH, Paran C, Vanderveen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, et al. Pre-clinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther. 2014.
Hong X, O'Donnell JP, Salazar CR, Van Brocklyn JR, Barnett KD, Pearl DK, Decarvalho AC, Ecsedy JA, Brown SL, Mikkelsen T, et al. The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation. Cancer Chemother Pharmacol. 2014.
2015
Giladi NDavid, Ziv-Av A, Lee HKyung, Finniss S, Cazacu S, Xiang C, Ben-Asher HWaldman, deCarvalho A, Mikkelsen T, Poisson L, et al. RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop. Oncotarget. 2015.
2016
Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 2016;164(5):1060-1072.
Jiang W, Finniss S, Cazacu S, Xiang C, Brodie, iv Z, Mikkelsen T, Poisson L, Shackelford DB, Brodie C. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget. 2016.
2020
Peereboom DM, Ye X, Mikkelsen T, Lesser GJ, Lieberman FS, H Robins I, Ahluwalia MS, Sloan AE, Grossman SA. A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. Neurosurgery. 2020.